Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections

References

• World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2008. World Health Organization, Geneva, Switzerland (2008).
   Google Scholar
• Stop TB Partnership. The Global Plan to Stop TB, 2006–2015: actions for life: towards a world free of tuberculosis. World Health Organization, Geneva, Switzerland (2006).
   Google Scholar
• Goldman RC, Plumley KV, Laughon BE. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect. Disord. Drug Targets7, 73–91 (2007).
   PubMedGoogle Scholar
• World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland (2006).
   Google Scholar
• Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial-efflux pumps. Curr. Drug Targets9, 816–819 (2008).
   PubMed Web of Science ®Google Scholar
• Martins M, Viveiros M, Couto I, Amaral L. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. Int. J. Tuberc. Lung Dis.13, 569–573 (2009).
   PubMed Web of Science ®Google Scholar
• Stricof RL, DiFerdinando GT Jr, Osten WM, Novick LF. Tuberculosis control in New York City hospitals. Am. J. Infect. Control26, 270–276 (1998).
   PubMed Web of Science ®Google Scholar
• Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Méndez A. Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984–1992. Am. J. Public Health91, 1487–1493 (2001).
   PubMed Web of Science ®Google Scholar
• Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York city – turning the tide. N. Engl. J. Med.333, 229–233 (1995).
   PubMed Web of Science ®Google Scholar
• Kamholz SL. Resurgence of tuberculosis: the perspective a dozen years later. J. Assoc. Acad. Minor Phys.7, 83–96 (1996).
   PubMedGoogle Scholar
• Frieden TR, Driver CR. Tuberculosis control: past 10 years and future progress. Tuberculosis (Edinb.)83, 82–85 (2003).
   PubMed Web of Science ®Google Scholar
• Salfinger M, Hale YM, Driscoll JR. Diagnostic tools in tuberculosis. Present and future. Respiration65, 163–170 (1998).
   PubMed Web of Science ®Google Scholar
• Paolo WF Jr, Nosanchuk JD. Tuberculosis in New York city: recent lessons and a look ahead. Lancet Infect. Dis.4, 287–293 (2004).
   PubMed Web of Science ®Google Scholar
• Antunes ML, Aleixo-Dias J, Antunes AF, Pereira MF, Raymundo F, Rodrigues MF. Anti-tuberculosis drug resistance in Portugal. Int. J. Tuberc. Lung Dis.4, 223–231 (2000).
   PubMed Web of Science ®Google Scholar
• Direcção Geral Saúde. Ponto da situação da Tuberculose em Portugal para o ano de 2007 – Dia Mundial da Tuberculose (TB) 2008 – Notas prévias. Ministério da Saúde, Lisboa, Portugal (2008).
   Google Scholar
• Portugal I, Barreiro L, Vultos T et al. Molecular epidemiology of Mycobacterium tuberculosis in Lisbon. Rev. Port. Pneumol.14, 239–259 (2008).
   PubMedGoogle Scholar
• Perdigão J, Macedo R, João I, Fernandes E, Brum L, Portugal I. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb. Drug Resist.14, 133–143 (2008).
   PubMed Web of Science ®Google Scholar
• Proença R. Reflexões sobre a tuberculose na actualidade. Rev. Port. Doenças Infecciosas21, 33–37 (1998).
   Google Scholar
• Antunes ML, Fonseca-Antunes A. The tuberculosis situation in Portugal: a historical perspective to 1994. Euro Surveill.1, 19–21 (1996).
   PubMedGoogle Scholar
• Portugal I, Covas MJ, Viveiros M, Ferrinho P, Moniz-Pereira J, David H. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism. Int. J. Tuberc. Lung Dis.3, 207–213 (1999).
   PubMed Web of Science ®Google Scholar
• Perdigão J, Macedo R, Malaquias A, Ferreira A, Brum L, Portugal I. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J. Antimicrob. Chemother.65(2), 224–227 (2010).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories 4th Edition. US Department of Health and Human Services. Public Health Service. US Government Printing Office, Washington, DC, USA (1999).
   Google Scholar
• Centers for Disease Control and Prevention and National Institutes of Health. Primary Containment for Biohazards: Selection, Installation and Use of Biological Safety Cabinets 2nd Edition. Department of Health and Human Services. Public Health Service. US Government Printing Office, Washington, DC, USA (2000).
   Google Scholar
• Centers for Disease Control and Prevention. Goals for Working Safely with Mycobacterium tuberculosis in Clinical, Public Health, and Research Laboratories Federal Register, USA (1997).
   Google Scholar
• Portugal I, Maia S, Moniz-Pereira J. Discrimination of multidrug-resistant Mycobacterium tuberculosis IS6110 fingerprint subclusters by rpoB gene mutation analysis. J. Clin. Microbiol.37, 3022–3024 (1999).
   PubMed Web of Science ®Google Scholar
• Viveiros M, Leandro C, Rodrigues L et al. Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis. J. Clin. Microbiol.43, 4880–4884 (2005).
   PubMed Web of Science ®Google Scholar
• Somoskovi A, Song Q, Mester J et al. Use of molecular methods to identify the Mycobacterium tuberculosis complex (MTBC) and other mycobacterial species and to detect rifampin resistance in MTBC isolates following growth detection with the BACTEC MGIT 960 system. J. Clin. Microbiol.41, 2822–2826 (2003).
   PubMed Web of Science ®Google Scholar
• Rossau R, Traore H, De Beenhouwer H et al. Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob. Agents Chemother.41, 2093–2098 (1997).
   PubMed Web of Science ®Google Scholar
• Tortolli E, Marcelli F. Use of the INNO LIPA Rif.TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur. J. Clin. Microbiol. Infect. Dis.26, 51–55 (2007).
   PubMed Web of Science ®Google Scholar
• World Health Organization. The WHO/IUTALD global project on anti-tuberculosis drug resistance surveillance, report no. 3, 1999–2002. World Health Organization, Geneva, Switzerland (2004).
   Google Scholar
• Ormerod LP. Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br. Med. Bull.74, 17–24 (2005).
   Web of Science ®Google Scholar
• Costeira J, Pina J. Multi-drug resistant tuberculosis and the red queen – diagnosis speed is crucial. Rev. Port. Pneumol.13, 869–877 (2007).
   PubMedGoogle Scholar
• Framework Action Plan to Fight Tuberculosis in the European Union. ECDC – European Centre for Disease Prevention and Control, Stockholm, Sweden (2008).
   Google Scholar
• Direcção-Geral da Saúde. Circular Normativa No. 12/DSCS/PNT. Detecção rápida da Tuberculose Multirresistente – Rapid Detection of Multidrug Resistant Tuberculosis. Portugal (2008).
   Google Scholar
• Ehrlich P. The Collected Papers of Paul Ehrlich. Himmelweit F, Marquardi M, Dale H (Eds). Pergammon Press, London, UK, 189–194 (1956).
   Google Scholar
• Amaral L, Kristiansen JE. Phenothiazines: an alternative to conventional management of suspect multidrug resistant tuberculosis. Int. J. Antimicrob. Agents14, 173–176 (2000).
   PubMed Web of Science ®Google Scholar
• Kaminska M. The role of chlorpromazine in the treatment of pulmonary tuberculosis in psychiatric patients. Folia Med. Cracoviensia9, 115–143 (1967).
   PubMedGoogle Scholar
• Libenson VS, Braude VI. The antitubercular effect of aminazin. Biull. Eksp. Biol. Med.63, 61–63 (1967).
   PubMedGoogle Scholar
• Molnár J, Béládi I, Földes I. Studies on antituberculotic action of some phenothiazine derivatives in vitro. Zentralbl. Bakteriol.239, 521–526 (1977).
   Google Scholar
• Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int. J. Antimicrob. Agents17, 225–228 (2001).
   PubMed Web of Science ®Google Scholar
• Kristiansen JE, Vergmann B. The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. Acta Pathol. Microbiol. Immunol. Scand. B94, 393–398 (1986).
   PubMedGoogle Scholar
• Amaral L, Kristiansen JE, Abebe LS, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. Chemother.38, 1049–1053 (1996).
   PubMed Web of Science ®Google Scholar
• Bettencourt-Viveiros M, Bosne-David S, Amaral L. Comparative activity of phenothiazines against multi-drug resistant Mycobacterium tuberculosis. Int. J. Antimicrob. Agents16, 69–71 (2000).
   PubMed Web of Science ®Google Scholar
• Ratnakar P, Rao SP, Sriramarao P, Murthy PS. Structure–antitubercular activity relationship of phenothiazine-type calmodulin antagonists. Int. Clin. Psychopharmacol.10, 39–43 (1995).
   PubMedGoogle Scholar
• Bate AB, Kalin JH, Fooksman EM et al. Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. Bioorg. Med. Chem. Lett.17, 1346–1348 (2007).
   PubMed Web of Science ®Google Scholar
• Martins M, Schelz Z, Martins A et al.In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents29, 338–340 (2007).
   PubMed Web of Science ®Google Scholar
• Amaral L, Kristiansen JE. Phenothiazines: potential management of Creutzfeldt Jakob disease and its variants. Int. J. Antimicrob. Agents18, 411–417 (2001).
   PubMed Web of Science ®Google Scholar
• Amaral L, Viveiros M, Molnar J. Antimicrobial activity of phenothiazines. In Vivo18, 725–732 (2004).
   Google Scholar
• Ishizaki J, Yokogawa K, Hirano M et al. Contribution of lysosomes to the subcellular distribution of basic drugs in the rat liver. Pharm. Res.13, 902–906 (1996).
   PubMed Web of Science ®Google Scholar
• Daniel WA, Wójcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol. Toxicol.80, 62–68 (1997).
   PubMedGoogle Scholar
• Daniel WA, Wójcikowski J. The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol. Appl. Pharmacol.158, 115–124 (1999).
   PubMed Web of Science ®Google Scholar
• Daniel WA, Wójcikowski J. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur. Neuropsychopharmacol.9, 483–491 (1999).
   PubMed Web of Science ®Google Scholar
• Wójcikowski J, Daniel WA. Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol. J. Pharmacol.52, 449–457 (2000).
   PubMedGoogle Scholar
• Crowle AJ, Douvas GS, May MH. Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy38, 410–419 (1992).
   PubMed Web of Science ®Google Scholar
• Ordway D, Viveiros M, Leandro C, Amaral L. Clinical concentrations of thioridazine kill intracellular multi-drug resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother.47, 917–922 (2003).
   PubMed Web of Science ®Google Scholar
• van Ingen J, Boeree M, Amaral L, Dekhuijzen R, van Soolingen D. In vitro activity of thioridazine against nontuberculous mycobacteria. Int. J. Antimicrob. Agents34, 190–191 (2009).
   PubMed Web of Science ®Google Scholar
• Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo21, 771–775 (2007).
   Google Scholar
• Amaral L. TB and phenothiazines. Scientist19, 8–10 (2005).
   Google Scholar
• Amaral L, Viveiros M, Kristiansen JE. “Non-antibiotics”: alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr. Drug Targets7, 887–891 (2006).
   PubMed Web of Science ®Google Scholar
• Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother.59, 1237–1246 (2007).
   PubMed Web of Science ®Google Scholar
• Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am. J. Health Syst. Pharm.65, 1029–1038 (2008).
   PubMed Web of Science ®Google Scholar
• Gongadze N, Kezeli T, Antelava N. Prolong QT interval and “torsades de pointes” associated with different group of drugs. Georgian Med. News153, 45–49 (2007).
   Google Scholar
• Mackin P. Cardiac side effects of psychiatric drugs. Hum. Psychopharmacol.23, 3–14 (2008).
   PubMed Web of Science ®Google Scholar
• Salih IS, Thanacoody RH, McKay GA, Thomas SH. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin. Pharmacol. Ther.82, 548–554 (2007).
   PubMed Web of Science ®Google Scholar
• Thanacoody HK. Thioridazine: resurrection as an antimicrobial agent? Br. J. Clin. Pharmacol.64, 566–574 (2007).
   PubMed Web of Science ®Google Scholar
• Amaral L, Martins M, Viveiros M. Phenothiazines as anti-multi-drug resistant tubercular agents. Infect. Disord. Drug Targets7, 257–265 (2007).
   PubMedGoogle Scholar
• Courmont P, Derries G. Antibiotic effect in vitro of R P 3277 on Koch’s bacilli. C. R. Seances Soc. Biol. Fil.145, 335–338 (1951).
   PubMedGoogle Scholar
• Daniel WA, Wojcikowski J. Interactions between promazine and antidepressants at the level of cellular distribution. Pharmacol. Toxicol.81, 259–264 (1997).
   PubMedGoogle Scholar
• Daniel WA, Wojcikowski J, Palucha A. Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. Br. J. Pharmacol.134, 807–814 (2001).
   PubMed Web of Science ®Google Scholar
• Gadre DV, Talwar V, Gupta HC, Murthy PS. Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis. Int. Clin. Psychopharmacol.13, 129–131 (1998).
   PubMed Web of Science ®Google Scholar
• Ratnakar P, Murthy PS. Trifluoperazine inhibits the incorporation of labelled precursors into lipids, proteins and DNA of Mycobacterium tuberculosis H37Rv. FEMS Microbiol. Lett.110, 291–294 (1993).
   PubMed Web of Science ®Google Scholar
• Salih FA, Kaushik NK, Sharma P, Choudary GV, Murthy PS, Venkitasubramanian TA. Calmodulin-like activity in mycobacteria. Indian J. Biochem. Biophys.28, 491–495 (1991).
   PubMed Web of Science ®Google Scholar
• Csiszar K, Molnar J. Mechanism of action of tricyclic drugs on Escherichia coli and Yersinia enterocolitica plasmid maintenance and replication. Anticancer Res.12, 2267–2272 (1992).
   PubMed Web of Science ®Google Scholar
• Molnár J, Földeák S, Nakamura MJ, Gaizer F, Gutmann F. The influence of charge transfer complex formation on the antibacterial activity of some tricyclic drugs. Xenobiotica21, 309–316 (1991).
   PubMed Web of Science ®Google Scholar
• Viveiros M, Portugal I, Bettencourt R et al. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother.46, 2804–2810 (2002).
   PubMed Web of Science ®Google Scholar
• Amaral L, Engi H, Viveiros M, Molnar J. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents. In Vivo21, 237–244 (2007).
   Google Scholar
• Viveiros M, Martins M, Couto I et al. New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. Curr. Drug Targets9, 760–778 (2008).
   PubMed Web of Science ®Google Scholar
• Viveiros M, Leandro C, Amaral L. Mycobacterial efflux pumps and chemotherapeutic implications. Int. J. Antimicrob. Agents22, 274–278 (2003).
   PubMed Web of Science ®Google Scholar
• Danilchanka O, Mailaender C, Niederweis M. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob. Agents Chemother.52, 2503–2511 (2008).
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang W, Zhang Y et al. Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb. Drug Resist.14, 7–11 (2008).
   PubMed Web of Science ®Google Scholar
• Escribano I, Rodríguez JC, Llorca B, García-Pachon E, Ruiz M, Royo G. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy53, 397–401 (2007).
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Liu W et al. Isoniazid’s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J. Infect. Dis.195, 194–201 (2007).
   PubMed Web of Science ®Google Scholar
• De La Iglesia AI, Morbidoni HR. Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends. Rev. Argent. Microbiol.38, 97–109 (2006).
   PubMedGoogle Scholar
• De Rossi E, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev.30, 36–52 (2006).
   PubMed Web of Science ®Google Scholar
• Tkachenko AG, Chudinov AA, Nagorskikh TG. Role of the energy status and putrescine transport in the maintenance of the intracellular pH homeostasis in the course of alkaline and acidic shifts in Escherichia coli. Mikrobiologiia62, 37–45 (1993).
   PubMedGoogle Scholar
• Bagramian KA, Vasilian AV, Trchunian AA. Character of K+ absorption and its interaction with membrane protein pumps in Escherichia coli, grown under anaerobic conditions in the presence of nitrate. Biofizika41, 377–383 (1996).
   PubMed Web of Science ®Google Scholar
• Ahluwalia J, Tinker A, Clapp LH et al. The large-conductance Ca2+ activated K+ channel is essential for innate immunity. Nature427, 853–858 (2004).
   PubMed Web of Science ®Google Scholar
• Reeves EP, Lu H, Jacobs HL et al. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature416, 291–297 (2002).
   PubMed Web of Science ®Google Scholar
• Kristiansen JE, Mortensen I, Nissen B. Membrane stabilizers inhibit potassium efflux from Staphylococcus aureus strain no. U2275. Biochim. Biophys. Acta685, 379–382 (1982).
   PubMedGoogle Scholar
• Martins M, Viveiros M, Amaral L. Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo22, 69–75 (2008).
   PubMed Web of Science ®Google Scholar
• Martins M, Bleiss W, Marko A et al. Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In Vivo18, 787–794 (2004).
   Google Scholar
• Allen LA, Aderem A. Mechanisms of phagocytosis. Curr. Opin. Immunol.8, 36–40 (1996).
   PubMed Web of Science ®Google Scholar
• Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin. Microbiol. Rev.16, 379–414 (2003).
   PubMed Web of Science ®Google Scholar
• Józefowski S, Sobota A, Kwiatkowska K. How Mycobacterium tuberculosis subverts host immune responses. Bioessays30, 943–954 (2008).
   PubMed Web of Science ®Google Scholar
• Tosteson DC. The cellular functions of active transport of K and Na. Physiol. Pharmacol. Physicians3, 1–6 (1965).
   PubMedGoogle Scholar
• Skou JC. Enzymatic basis for active transport of Na+ and K+ across cell membrane. Physiol. Rev.45, 596–617 (1965).
   PubMed Web of Science ®Google Scholar
• Schoner W. Active transport of Na+ and K+ through animal cell membranes. Angew. Chem. Int. Ed. Engl.10, 882–889 (1971).
   PubMed Web of Science ®Google Scholar
• Fairbairn IP, Stober CB, Kumararatne DS. ATP-mediated killing of intracellular mycobacteria by macrophages is a P2X7-dependent process inducing bacterial death by phagosome–lysosome fusion. J. Immunol.167, 3300–3307 (2001).
   PubMed Web of Science ®Google Scholar
• Kusner DJ, Barton JA. ATP stimulates human macrophages to kill intracellular virulent Mycobacterium tuberculosis via calcium-dependent phagosome–lysosome fusion. J. Immunol.167, 3308–3315 (2001).
   PubMed Web of Science ®Google Scholar
• Pillay CS, Elliott E, Dennison C. Endolysosomal proteolysis and its regulation. Biochem. J.363, 417–429 (2002).
   PubMed Web of Science ®Google Scholar
• Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol. Cell Biol.85, 103–111 (2007).
   PubMed Web of Science ®Google Scholar
• Martins M, Ordway D, Kristiansen M et al. Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus. Fitoterapia76, 96–99 (2005).
   PubMed Web of Science ®Google Scholar
• Ordway D, Hohmann J, Viveiros M et al.Carpobrotus edulis methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation. Phytother. Res.17, 512–519 (2003).
   PubMed Web of Science ®Google Scholar
• Ordway D, Viveiros M, Leandro C et al. Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J. Infect. Chemother.8, 227–231 (2002).
   PubMedGoogle Scholar
• Ordway D, Viveiros M, Leandro C, Arroz MJ, Amaral L. Intracellular activity of clinical concentrations of phenothiazines including thioridazine against phagocytosed Staphylococcus aureus. Int. J. Antimicrob. Agents20, 34–43 (2002).
   PubMed Web of Science ®Google Scholar
• Abbate E, Vescovo M, Natiello M et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacables epidemiológicos, bacteriológicos, terapéuticos y evolutivos. Revista Argentina de Medicina Respiratoria1, 19–25 (2007).
   Google Scholar
• World Health Organization. Report of the meeting of the WHO Global Task Force on XDR-TB. World Health Organization, Geneva, Switzerland (2006).
   Google Scholar
• Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev. Mol. Diagn.6, 423–432 (2006).
   PubMed Web of Science ®Google Scholar
• Palomino JC. Newer diagnostics for tuberculosis and multi-drug resistant tuberculosis. Curr. Opin. Pulm. Med.12, 172–178 (2006).
   PubMed Web of Science ®Google Scholar
• Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents. DOI:10.1016/j.ijantimicag.2009.12.019 (2010) (Epub ahead of print).
   Google Scholar